✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹4,825 Cr.
P/E
37.62

Key Ratios

Market cap
Market cap
4,825 Cr
PE
PE
37.62
Prom Holding
Prom Holding
50.90 %
ROE (%)
ROE (%)
11.35
ROCE (%)
ROCE (%)
14.58
Div Yield (%)
Div Yield (%)
-
Sales
Sales
1,243 Cr
OPM (%)
OPM (%)
14.97 %
Debt to Equity
Debt to Equity
0.29
About
Innova Captab Limited, formerly known as Innova Captab Private Limited, is an Indian company b… Read more
Low
494
52W Range
High
1260
  • Innova Captab
  • Sequent Scientific
  • Suven Life Sciences

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

6 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Peer Comparison
FAQs on Innova Captab Ltd. Business

Innova Captab, a Company domiciled in India with its registered office situated in Mulund (W), Mumbai, was incorporated in Mumbai on January 3, 2005 as a private limited company. The company was initially incorporated with the name of “I larun Healthcare Private Limited” and later the name was changed to “Innova Captab Private Limited”. The company was converted to a Public Limited Company w.e.f July 26, 2018. After conversion, the name of the Company is “Innova Captab Limited”. The company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals.

Innova Captab major competitors are Sequent Scientific, Suven Life Sciences, Hikal, Supriya Lifescience, Unichem Lab, Aarti Drugs, RPG Life Sciences.
Market Cap of Innova Captab is ₹4,913 Crs.
While the median market cap of its peers are ₹4,432 Crs.

Innova Captab seems to be less financially stable compared to its competitors.
Altman Z score of Innova Captab is 8.13 and is ranked 4 out of its 8 competitors.

Company Filing
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release May Mar Jun Sep Dec
Investor Presentation May Feb Mar Jun Sep Dec Dec
Conference Call May Mar Jun Sep Dec Dec
Conference Call SummaryCon Call Summary
Discussions & Analysis
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material